Fired Genentech employee sues for wrongful termination over whistleblower complaints
This article was originally published in Scrip
Former Genentech employee Juliet Kniley filed a lawsuit in San Mateo County Superior Court against the Roche subsidiary, claiming retaliation and wrongful termination under California state law after she complained repeatedly about her superiors' alleged unwillingness to follow the clinical trial protocol for an unnamed phosphoinositide-3-kinase (PI3K) inhibitor.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.